Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
14/10/2026 08:02
BRIEF-Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets Oct 14 (Reuters) - Nxera Pharma Co., Ltd. 4565.T:
ENTERED INTO EXCLUSIVE LICENSE, SUPPLY AND COMMERCIALIZATION AGREEMENT WITH SYNMOSA FOR QUVIVIQ ACROSS EIGHT ASIA-PACIFIC MARKETS
Source text: ID:nTSvn865b9
Further company coverage: 4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up